These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 8851631

  • 1. Hemodynamic and cardiac effects of BMS-180448, a novel K+ATP opener, in anesthetized dogs and isolated rat hearts.
    D'Alonzo AJ, Grover GJ, Darbenzio RB, Sewter JC, Hess TA, Dzwonczyk S, Sleph PG.
    Pharmacology; 1996 Feb; 52(2):101-12. PubMed ID: 8851631
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
    Grover GJ, McCullough JR, D'Alonzo AJ, Sargent CA, Atwal KS.
    J Cardiovasc Pharmacol; 1995 Jan; 25(1):40-50. PubMed ID: 7723352
    [Abstract] [Full Text] [Related]

  • 4. Cardiovascular effects of KRN2391 in anesthetized dogs: a comparison with cromakalim and nitroglycerin.
    Kaneta S, Yokoyama T, Izumi H, Izawa T, Ogawa N.
    Arch Int Pharmacodyn Ther; 1994 Jan; 327(2):184-93. PubMed ID: 7979827
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Regional hemodynamic dose-response of lemakalim and glybenclamide in anesthetized rats.
    Smits GJ, Perrone MH, Cox BF.
    J Cardiovasc Pharmacol; 1997 Jan; 29(1):49-56. PubMed ID: 9007670
    [Abstract] [Full Text] [Related]

  • 8. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
    Grover GJ, D'Alonzo AJ, Garlid KD, Bajgar R, Lodge NJ, Sleph PG, Darbenzio RB, Hess TA, Smith MA, Paucek P, Atwal KS.
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effects of a K+ATP channel opener, lemakalim, on systemic, coronary and regional vascular dynamics in conscious dogs: comparison with nifedipine, adenosine, nitroglycerin and acetylcholine.
    Shen YT, Vatner SF.
    J Pharmacol Exp Ther; 1993 May; 265(2):1026-37. PubMed ID: 8496801
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs.
    Grover GJ, Sleph PG, Dzwonczyk S.
    J Cardiovasc Pharmacol; 1990 Dec; 16(6):853-64. PubMed ID: 1704976
    [Abstract] [Full Text] [Related]

  • 15. Preclinical pharmacology of Ro 31-6930, a new potassium channel opener.
    Paciorek PM, Burden DT, Burke YM, Cowlrick IS, Perkins RS, Taylor JC, Waterfall JF.
    J Cardiovasc Pharmacol; 1990 Feb; 15(2):188-97. PubMed ID: 1689412
    [Abstract] [Full Text] [Related]

  • 16. The antihypertensive and cardioprotective effects of (-)-MJ-451, an ATP-sensitive K(+) channel opener.
    Lee YM, Yen MH, Peng YY, Sheu JR, Chen YC, Chang MJ, Cheng CY.
    Eur J Pharmacol; 2000 May 26; 397(1):151-60. PubMed ID: 10844109
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cardiovascular effects of the novel potassium channel opener UR-8225.
    Tamargo J, Pérez O, Delpón E, García-Rafanell J, Gómez L, Cavalcanti F.
    J Cardiovasc Pharmacol; 1995 Aug 26; 26(2):295-305. PubMed ID: 7475055
    [Abstract] [Full Text] [Related]

  • 19. Limitation of myocardial injury with the potassium channel opener cromakalim and the nonvasoactive analog U-89,232: vascular vs. cardiac actions in vitro and in vivo.
    Toombs CF, Norman NR, Groppi VE, Lee KS, Gadwood RC, Shebuski RJ.
    J Pharmacol Exp Ther; 1992 Dec 26; 263(3):1261-8. PubMed ID: 1469632
    [Abstract] [Full Text] [Related]

  • 20. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
    Grover GJ, D'Alonzo AJ, Hess T, Sleph PG, Darbenzio RB.
    Cardiovasc Res; 1995 Nov 26; 30(5):731-8. PubMed ID: 8595620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.